Market Cap 118.43M
Revenue (ttm) 0.00
Net Income (ttm) -23.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 624,900
Avg Vol 1,056,272
Day's Range N/A - N/A
Shares Out 100.36M
Stochastic %K 64%
Beta 1.24
Analysts Strong Sell
Price Target $4.12

Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoin...

Industry: Biotechnology
Sector: Healthcare
Phone: 403-670-7377
Fax: 403-283-0858
Address:
322 11th Avenue SW, Suite 804, Calgary, Canada
charlietwodogs
charlietwodogs Oct. 25 at 8:02 PM
$ONCY not sure why the stock house site is still up... onc is not listed in Canada anymore
0 · Reply
charlietwodogs
charlietwodogs Oct. 25 at 1:17 AM
$ONCY ole Jared must have been matt coffys understudy... a chip off the ole block.
0 · Reply
charlietwodogs
charlietwodogs Oct. 25 at 1:15 AM
$ONCY a dime hell... we need dollars!!!
0 · Reply
GoPatzGo123
GoPatzGo123 Oct. 24 at 5:23 PM
$ONCY a penny here a penny there...WTF ??? Give us at least a dime or higher . Been like this for many many years
1 · Reply
robo1470
robo1470 Oct. 24 at 2:22 PM
$ONCY tick tok tick tok FDA Meeting coming soon if they can get this to phase 3 I think we go up to $3 min. just my opinion
1 · Reply
stocktowatchs
stocktowatchs Oct. 24 at 2:17 PM
$ONCY Buy average On barchart https://www.barchart.com/stocks/quotes/ONCY/opinion
0 · Reply
stocktowatchs
stocktowatchs Oct. 24 at 1:41 PM
0 · Reply
Risk1123
Risk1123 Oct. 24 at 1:26 PM
0 · Reply
stocktowatchs
stocktowatchs Oct. 24 at 9:22 AM
$ONCY looks prime to Bounce and thin - IMO
0 · Reply
Notable_Ex
Notable_Ex Oct. 23 at 7:18 PM
$ONCY Roche clears out its Chinese holdings. https://www.fiercebiotech.com/biotech/roche-axes-4-chugai-solid-tumor-assets-early-phase-clearout
0 · Reply
Latest News on ONCY
Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:21 PM EDT - 5 months ago

Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript


Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript

Mar 7, 2025, 11:11 AM EST - 8 months ago

Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript


charlietwodogs
charlietwodogs Oct. 25 at 8:02 PM
$ONCY not sure why the stock house site is still up... onc is not listed in Canada anymore
0 · Reply
charlietwodogs
charlietwodogs Oct. 25 at 1:17 AM
$ONCY ole Jared must have been matt coffys understudy... a chip off the ole block.
0 · Reply
charlietwodogs
charlietwodogs Oct. 25 at 1:15 AM
$ONCY a dime hell... we need dollars!!!
0 · Reply
GoPatzGo123
GoPatzGo123 Oct. 24 at 5:23 PM
$ONCY a penny here a penny there...WTF ??? Give us at least a dime or higher . Been like this for many many years
1 · Reply
robo1470
robo1470 Oct. 24 at 2:22 PM
$ONCY tick tok tick tok FDA Meeting coming soon if they can get this to phase 3 I think we go up to $3 min. just my opinion
1 · Reply
stocktowatchs
stocktowatchs Oct. 24 at 2:17 PM
$ONCY Buy average On barchart https://www.barchart.com/stocks/quotes/ONCY/opinion
0 · Reply
stocktowatchs
stocktowatchs Oct. 24 at 1:41 PM
0 · Reply
Risk1123
Risk1123 Oct. 24 at 1:26 PM
0 · Reply
stocktowatchs
stocktowatchs Oct. 24 at 9:22 AM
$ONCY looks prime to Bounce and thin - IMO
0 · Reply
Notable_Ex
Notable_Ex Oct. 23 at 7:18 PM
$ONCY Roche clears out its Chinese holdings. https://www.fiercebiotech.com/biotech/roche-axes-4-chugai-solid-tumor-assets-early-phase-clearout
0 · Reply
canuck_trader92
canuck_trader92 Oct. 23 at 6:34 PM
$ONCY Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada - Anyone know what this is about?
0 · Reply
charlietwodogs
charlietwodogs Oct. 22 at 11:30 PM
$ONCY pumpers... don't let the door hit you... where the good lord split you...
2 · Reply
charlietwodogs
charlietwodogs Oct. 22 at 10:08 PM
$ONCY pumpers are like Custer's last stand...
1 · Reply
charlietwodogs
charlietwodogs Oct. 22 at 9:16 PM
$ONCY will loose it tomorrow!!!
1 · Reply
m00nsh0t
m00nsh0t Oct. 22 at 9:15 PM
$ONCY TODAY WAS A GOOD DAY
1 · Reply
charlietwodogs
charlietwodogs Oct. 22 at 9:00 PM
$ONCY pumpers are getting worried.
1 · Reply
FoxM07
FoxM07 Oct. 22 at 8:50 PM
$ONCY please report as spam.
1 · Reply
Notable_Ex
Notable_Ex Oct. 22 at 8:45 PM
$ONCY Certain posters here are indisputably vexatious. Ask yourselves why !
0 · Reply
FoxM07
FoxM07 Oct. 22 at 8:36 PM
$ONCY pls report as spam. The desperation will only get worse.
1 · Reply
Notable_Ex
Notable_Ex Oct. 22 at 8:28 PM
$ONCY In 2025, commercial-stage biotech companies—particularly those in oncology and immunotherapy like Oncolytics Biotech—are typically valued using Enterprise Value-to-Sales (EV/Sales) multiples that range from 4x to 10x annual revenue, depending on product maturity, exclusivity, and competitive positioning. n summary, active commercial biotechs are generally valued between 5×–10× annual sales, with immuno‑oncology assets at the higher end of that range, particularly when they have limited competition or breakthrough designation prospects. So you do the math simply based on PDAC projected annual sales, then factor in anal, GI, CRC and breast cancer forward sales for ONCY's 'real' valuation level.
1 · Reply
FoxM07
FoxM07 Oct. 22 at 8:18 PM
$ONCY report wild baseless conjecture as spam. Time for a clean up moderators. Thank you.
1 · Reply
Notable_Ex
Notable_Ex Oct. 22 at 8:16 PM
$ONCY As posted on SHouse "M&A valuation based on 3 -5x annual PDAC sales alone = $12 Billion to $20 Billion. Then factor in annual sales from anal, CRC and breast cancers to get a more 'realistic' valuation level. In 2025, commercial-stage biotech companies—particularly those in oncology and immunotherapy like Oncolytics Biotech—are typically valued using Enterprise Value-to-Sales (EV/Sales) multiples that range from 4x to 10x annual revenue, depending on product maturity, exclusivity, and competitive positioning. So you do the arithmatic.
1 · Reply